<<...informal inquiry which appears to be related to disclosures regarding the approval process for Provenge and trading in the Company’s stock.>>
One other way this language could be interpreted: it's highly possible (at least a 50-50 chance) that in regards to the "disclosures regarding the approval process" phrase, the SEC is investigating the manner in which DNDN disclosed the CR letter from the FDA, and not investigating the FDA's decision process at all.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.